Jan 2026· Pulmonary Medicine· Vol 2026· 0 citations· 137 references
Medicine
TL;DR
Challenges related to cost‐effective scalability, accessibility of advanced diagnostics, and optimization of therapeutic systems continue to limit clinical translation and future research must prioritize multidisciplinary collaborations to accelerate drug development, enhance diagnostic capabilities, and expand nanotechnology‐based solutions to address the TB epidemic effectively.
Abstract
The increasing prevalence of multidrug‐resistant (MDR) and extensively drug‐resistant (XDR)Mycobacterium tuberculosis has emerged as a major global health concern. Advanced molecular diagnostics, including rapid assays, have improved resistance detection; however, resource‐limited settings remain underserved. Nanotechnology‐based drug delivery systems, including polymeric carriers, solid lipid nanoparticles, and silver nanoparticles, can provide targeted delivery, prolonged release, and improved bioavailability. Drug repurposing strategies using existing drugs like linezolid, celecoxib, and nitazoxanide also show a promising option in combating drug‐resistant TB while reducing treatment duration. Host‐directed therapies (HDTs) and natural products offer complementary strategies by enhancing host immune responses and providing multitarget antimycobacterial effects. This review emphasizes the drug resistance mechanisms and advancements in novel theranostics. Despite significant progress, challenges related to cost‐effective scalability, accessibility of advanced diagnostics, and optimization of therapeutic systems continue to limit clinical translation. Future research must prioritize multidisciplinary collaborations to accelerate drug development, enhance diagnostic capabilities, and expand nanotechnology‐based solutions to address the TB epidemic effectively.
Antimicrobial resistance (AMR) is a major global health threat, driven by the spread of multidrug-resistant (MDR) pathogens alongside a declining antibiotic pipeline. Drug repurposing offers a cost-effective, time-efficient alternative by identifying antimicrobial applications for approved drugs with established safety...
Meer M. Abdulkarim, F. Fattah, A. G. Hamasaeed et al.· Journal of Applied Microbiol...· 0 citations
Tuberculosis (TB) remains a leading cause of global mortality. Its prevention and control face major challenges, including a large latent infection reservoir, high transmissibility, complex treatment protocols, rising drug-resistant TB (notably multidrug-resistant TB, MDR-TB), and comorbidities. MDR-TB has severely und...
Recent advances in nanotechnology-based strategies for combating AMR are summarized, highlighting the mechanisms of action, therapeutic applications, current research progress, and future translational prospects.
P. Swami, Priya D. Chouragade· Journal of Drug Delivery and...· 0 citations
This review critically evaluates current computational strategies for anti-TB drug screening, with particular emphasis on their performance under TB-specific biological and resistance constraints, and proposes a shift toward biologically grounded, regimen-aware, and systems-level frameworks.
Shan-Shan Hu, Xiao-Yu Li, Z. Batool et al.· Frontiers in Pharmacology· 0 citations
Antimicrobial resistance is a growing global health challenge, with conventional antibiotics increasingly failing against multidrug-resistant and biofilm-associated infections. Nanotechnology offers promising solutions through enhanced antimicrobial activity, targeted drug delivery, and rapid diagnostics. This review d...
Soumitra Nath· Nanofabrication· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.